NOTE! 1. NFA (Not Financial Advice!) 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If you don’t a...
$Exagen (XGN.US)$ Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results Sunday, 12th January at 12:00 pm New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:...
$Exagen (XGN.US)$ Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Analysts predict Exagen's revenue growth to decelerate significantly, with an expected annual growth of 3.1% till 2024, compared to its past five-year growth rate of 7.5%. This is slower than the projected 18% annual growth of its industry peers.
The low P/S ratio and slower revenue growth have led to pessimism among shareholders about the company's future prospects. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
Exagen's low P/S ratio indicates investor concerns over below-average expected revenue growth. For a higher P/S ratio or share price, conditions would need to improve. The recent drop in share price may be due to this potentially less favorable outlook.
Exagen Stock Forum
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Sunday, 12th January at 12:00 pm
New biomarkers on track for commercial launch in January 2025
Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
No comment yet